Literature DB >> 6192907

In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells.

G Fabre, L H Matherly, R Favre, J Catalin, J P Cano.   

Abstract

The intracellular synthesis of polyglutamyl derivatives of both methotrexate (4-amino-N-10-methylpteroylglutamic acid) and 7-hydroxymethotrexate, the primary plasma metabolite of methotrexate in humans, was evaluated in a methotrexate-sensitive, acute lymphoblastic leukemia cell line, MOLT 4. These studies were performed using a highly specific ion-pairing high-pressure liquid chromatography method which permits the simultaneous determination of methotrexate, 7-hydroxymethotrexate, and their corresponding polyglutamyl derivatives. When MOLT 4 cells were exposed to 1 microM methotrexate, the monoglutamate attained a steady state after 30 min, and polyglutamyl derivatives having from one to 4 additional glutamyl residues were observed over 4 hr. Four additional metabolites were also detected upon incubation with 1 microM 7-hydroxymethotrexate. On the basis of the retention times for these compounds relative to methotrexate polyglutamyl standards and since these metabolites reverted to 7-hydroxymethotrexate upon treatment with a preparation of hog kidney conjugase, they were identified as polyglutamyl derivatives of 7-hydroxymethotrexate. The identification of 7-hydroxymethotrexate polyglutamyl derivatives in vitro raises the possibility of an important new dimension in the pharmacological action of methotrexate. We investigated the effect of extracellular 7-hydroxymethotrexate on net methotrexate uptake and metabolism when cells were exposed simultaneously to 1 microM [3H]-methotrexate and unlabeled 7-hydroxymethotrexate. A decrease in the levels of both intracellular methotrexate and the corresponding polyglutamyl derivatives was noted for cells treated with 1 or 10 microM 7-hydroxymethotrexate. However, no appreciable effect of 7-hydroxymethotrexate on the amount of polyglutamyl derivatives formed relative to the total intracellular antifolate was noted. These studies show that in MOLT 4 cells (a) both methotrexate and 7-hydroxymethotrexate are rapidly converted to polyglutamyl derivatives, and (b) 7-hydroxymethotrexate interferes with net methotrexate accumulation and metabolism when present simultaneously in the extracellular medium. These results, moreover, suggest a potential role for 7-hydroxymethotrexate in modulating the biochemical effects of methotrexate in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192907

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

Authors:  C Wolfrom; R Hepp; R Hartmann; H Breithaupt; G Henze
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

3.  Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

Authors:  R Erttmann; S Bielack; G Landbeck
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography.

Authors:  B Payet; G Fabre; N Tubiana; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Germline genomic variants associated with childhood acute lymphoblastic leukemia.

Authors:  Lisa R Treviño; Wenjian Yang; Deborah French; Stephen P Hunger; William L Carroll; Meenakshi Devidas; Cheryl Willman; Geoffrey Neale; James Downing; Susana C Raimondi; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Nat Genet       Date:  2009-08-16       Impact factor: 38.330

7.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

Authors:  Deborah French; Wenjian Yang; Cheng Cheng; Susana C Raimondi; Charles G Mullighan; James R Downing; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

8.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Protection of cells from methotrexate toxicity by 7-hydroxymethotrexate.

Authors:  J M Gaukroger; L Wilson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.